TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01506622
Drug: Administration of saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be administered to control group at the end of anesthesia.
Study: NCT01501448
Drug: Levonorgestrel and ethinylestradiol
Normalized name: levonorgestrel and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days
Study: NCT00627731
Drug: prednisolone (PSL)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PSL 40 mg per day for 10 days
Study: NCT01995032
Drug: 750 mg metformin and 7.5 g L-citrulline daily p.o.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01995032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02837198
Drug: FYU-981
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01900704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02760069
Drug: Inhaled isopropyl alcohol
Normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
Study: NCT02760069
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00
Study: NCT02882009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.
Study: NCT01777100
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil 0.5 mcg.kg-1 at anesthesia induction (single dose)
Study: NCT02063022
Drug: Standard treatment (as per protocol ISG SSG III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)
Study: NCT02447315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03944460
Drug: Contraloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of capsules, drug substance or placebo without any excipients.
Study: NCT01235962
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching pazopanib was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
Study: NCT01235962
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
Study: NCT01074138
Drug: KX2-391
Approvals — FDA: no, EMA: no, PMDA: no
Description: KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.
Study: NCT04073069
Drug: The R group
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 15 ml 1% ropivacaine and 15 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Study: NCT01754935
Drug: VX-509 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg oral tablet
Study: NCT04344444
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablets provided as described in Arm C
Study: NCT02048891
Drug: hCG trigger
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03583489
Drug: APD421
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg IV
Study: NCT03583489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT02486432
Drug: Levodopa/Carbidopa (Sinemet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
Study: NCT00674700
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sublingual tablet daily for one year
Study: NCT03490097
Drug: Simvastatin 10mg
Normalized name: SIMVASTATIN 10MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets
Study: NCT02310568
Drug: PF-06372865.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
Study: NCT02222974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255604
Drug: Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4
Study: NCT02255604
Drug: alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 injection into a lymphnode
Study: NCT02255604
Drug: 0.1 ml Isoton saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 injection into a lymphnode
Study: NCT02301052
Drug: placebo topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo topical cream 2 cc twice daily for 3 weeks
Study: NCT02301052
Drug: Anti-hemorrhoid topical cream
Normalized name: Americaine Hemorrhoidal Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti hemorrhoid topical cream 2 cc twice daily for 3 weeks(This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w). 30 g )
Study: NCT04617509
Drug: Formulation B GS-248
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
Study: NCT00284271
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00284271
Drug: Procarbacine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03922555
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.
Study: NCT01269658
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
Study: NCT00840203
Drug: Mesalamine 4 gm/60 mL Rectal Enema
Normalized name: Mesalamine 4 GM/60 ML Rectal Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 4 gm/60 mL, single-dose
Study: NCT04340401
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
Study: NCT01179854
Drug: Remegal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug/ placebo
Study: NCT01325415
Drug: NKTR-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tablet
Study: NCT01325415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT01506167
Drug: Capecitabine/Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
Study: NCT01506167
Drug: Fluorouracil/Folinic Acid/Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
Study: NCT01506167
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine was administered along with bevacizumab as part of standard first-line treatment
Study: NCT01506167
Drug: Fluorouracil/Folinic Acid/Irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment
Study: NCT01506167
Drug: Fluorouracil +/- Folinic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
Study: NCT00321802
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients take 40 mg of simvastatin per day for 6 months.
Study: NCT00321802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02468115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose of placebo
Study: NCT00694785
Drug: ARC1779
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.~Group NT3
Study: NCT00694785
Drug: ARC1779
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.~Group T3
Study: NCT00694785
Drug: ARC1779
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.~Group NT6
Study: NCT00694785
Drug: ARC1779
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.~Group T6
Study: NCT03716024
Drug: PTK 0796
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTK 0796 100 mg for injection; PTK 0796 capsule 100 mg
Study: NCT00783003
Drug: GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Long acting Beta 2 agonist (LABA)
Study: NCT00783003
Drug: GSK233705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
Study: NCT00783003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo.
Study: NCT01705639
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All subjects receive the same dose of melatonin
Study: NCT01803373
Drug: Treatment A (reference)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
Study: NCT01803373
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
Study: NCT03721653
Drug: L-Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/sqm iv over 2 hours day 1
Study: NCT05806177
Drug: AD16 30mg、40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
Study: NCT05806177
Drug: AD16 Placebo 30mg、40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
Study: NCT00960778
Drug: nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.
Study: NCT02460302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppository inserted vaginally
Study: NCT00975650
Drug: Nasobol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-nasal Testosterone (2 syringes), b.i.d.
Study: NCT00975650
Drug: Androderm® (Positive Control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD administration
Study: NCT01919125
Drug: IDX719
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX719 supplied as 50 mg tablets.
Study: NCT02025660
Drug: Mw, 0.3ml x three days sc
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02025660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00035334
Drug: NC-503 (Anti-amyloidotic (AA) Agent)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02834507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules
Study: NCT02834507
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing nebicapone 75 mg or 150 mg
Study: NCT02834507
Drug: Comtan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing entacapone 200 mg
Study: NCT02834507
Drug: Sinemet®
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa/carbidopa (Sinemet®) dose patient used to take
Study: NCT00817024
Drug: Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
Study: NCT00817024
Drug: Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks
Study: NCT00817024
Drug: Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
Study: NCT00500201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be administered orally by subjects.
Study: NCT00622245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: per oral doses, twice daily as capsules during 13 weeks
Study: NCT03334734
Drug: PBTZ169
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day for 14 days
Study: NCT03370601
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mercaptopurine 1 à 1,5 mg/kg
Study: NCT03370601
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine 2 à 2.5mg/kg/j
Study: NCT00299975
Drug: MaZiRenWan (MZRW) Median dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
Study: NCT04177719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo will be given intranasally. The order of administration will be counterbalanced
Study: NCT01358903
Drug: RO5429083
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts receiving multiple escalating doses iv
Study: NCT01358903
Drug: RO5429083
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression
Study: NCT00395369
Drug: intraoperative aprotinin administration
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02845336
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib 100mg PO twice per day for 3 months
Study: NCT03217097
Drug: Alkylating-based chemotherapy
Normalized name: petroleum alkylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week).
Study: NCT02590081
Drug: Dextrose 5%
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02590081
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00880828
Drug: Acetaminophen only
Normalized name: Acetaminophen only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen QID/PRN for 4 weeks
Study: NCT05188911
Drug: Androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients would get medical or surgical castration.
Study: NCT04248179
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9%
Study: NCT00959764
Drug: Oral Calcitonin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Calcitonin tablets along with matching placebo intranasal spray
Study: NCT00959764
Drug: Intranasal Calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Calcitonin Spray
Study: NCT00959764
Drug: Placebo tablets and placebo intranasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo Tablets/Intranasal placebo spray
Study: NCT03863249
Drug: ADJUNTIVE ANTIBIOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The antimicrobial adjunctive agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit.~The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN.
Study: NCT03740945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of one placebo vaginal ovule at bedtime
Study: NCT03740945
Drug: Prasterone (DHEA)
Normalized name: prasterone (DHEA)
DrugBank: Prasterone sulfate (DB05804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily administration of one prasterone vaginal ovule at bedtime
Study: NCT01135199
Drug: pomalidomide (CC-4047
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04248179
Drug: Sufentanil and PONV prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minutes prior to emergence 0.2 μg/kg total body weight Sufentanil IV and 1 gram of paracetamol IV (if 6hrs since preoperative medicine) and 4 mg ondansetron IV (PONV prophylaxis) will be administered.
Study: NCT00254449
Drug: NGX-4010
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01619774
Drug: GSK2118436
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 150 mg by mouth twice a day.
Study: NCT01619774
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg by mouth daily.
Study: NCT02337257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will receive placebo one pill per day for 16 weeks
Study: NCT03780608
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.
Study: NCT00469183
Drug: Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically daily for 12 weeks and continue until condition is clear or almost clear for up to 24 weeks; Maintenance phase: Apply topically twice weekly until the end of study (24 weeks) or condition relapses
Study: NCT04391127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of placebo PO every 12 hours for one day. Subsequently one tablet of placebo every 12 hours per 4 more days.
Study: NCT00267384
Drug: Oral N-Acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02231723
Drug: BBI608
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered continuously twice daily with doses separated by 12 hours
Study: NCT02231723
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm C, D: Leucovorin 400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
Study: NCT02231723
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm B, D: Fluorouracil 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m\^2 I.V. bolus followed by 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
Study: NCT02289417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01988636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01802931
Drug: GSK239512
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3 receptor antagonist, potential victim of drug-drug interaction
Study: NCT05315128
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A randomized comparative effectiveness clinical trial
Study: NCT03068481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT00858780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator once weekly + methotrexate
Study: NCT01270776
Drug: 2% Chlorhexidine 70% isopropyl alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
Study: NCT04360915
Drug: ASK120067
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take ASK120067 tablets orally in first day at 160 mg in fast condition.
Study: NCT04133311
Drug: Xalatan®/DE-130A
Approvals — FDA: no, EMA: no, PMDA: no
Description: From week 12 onwards, DE-130A was continued to be administered instead of Xalatan®.
Study: NCT00313378
Drug: Hypothetica
Approvals — FDA: no, EMA: no, PMDA: no